back to Australia directory
australia clinical guidance

Eczema (atopic)

A detailed Australian summary of eczema (atopic), with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Assess distribution, severity, sleep loss, infection, irritant and allergic triggers, treatment use and the effect on the patient and family. Daily emollient and soap-substitute care supports the barrier; prescribe topical corticosteroid potency by site and flare severity with practical quantity instructions. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:ASCIA eczema plan

The Bottom Line

  • Assess distribution, severity, sleep loss, infection, irritant and allergic triggers, treatment use and the effect on the patient and family.
  • Daily emollient and soap-substitute care supports the barrier; prescribe topical corticosteroid potency by site and flare severity with practical quantity instructions.
  • Face, folds, eyelids and genital skin require lower-potency or steroid-sparing choices than thick plaques on trunk or limbs.
  • Demonstrate application and address corticosteroid concerns directly, because undertreatment and inconsistent use commonly mimic treatment failure.
sources for this section:ASCIA eczema plan

Practical clinical workflow

1

Topic-specific assessment action

Assess distribution, severity, sleep loss, infection, irritant and allergic triggers, treatment use and the effect on the patient and family.
2

Topic-specific diagnostic action

Demonstrate application and address corticosteroid concerns directly, because undertreatment and inconsistent use commonly mimic treatment failure.
3

Topic-specific management action

Treat clinically infected eczema according to the local antimicrobial pathway, but do not use routine antibiotics for every weeping flare.
4

Topic-specific follow-through

Bleach baths or decolonisation should be reserved for recurrent-infection pathways and not prescribed as universal eczema care.
sources for this section:ASCIA eczema plan

Safety boundaries and escalation

  • Urgently assess eczema herpeticum, eye involvement, widespread blistering, fever, rapid deterioration or severe disease causing dehydration or failure to thrive.
  • Growth, sleep, school attendance and caregiver exhaustion are important severity measures in children and can justify specialist referral.
sources for this section:ASCIA eczema plan

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:ASCIA eczema plan

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:ASCIA eczema plan

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Australasian Society of Clinical Immunology and AllergyASCIA Stepwise Management Plan for EczemaMarch 2022 management plan; current resource status checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.